Figure 3.
The percentage of proviral HIV-1 DNA genotyping yielding resistance-associated mutations conferring resistance to individual antiretroviral is compared with that past RNA genotyping or synchronous RNA genotyping. (A) Group 1 and (B) Group 2.
Abbreviations: ABC, abacavir; AZT, zidovudine; FTC, emtricitabine; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; DOR, doravirine; EFV, efavirenz; ETR, etravirine; NVP, nevirapine; RPV, rilpivirine; ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; IDV/r, ritonavir-boosted indinavir; LPV/r, ritonavir-boosted lopinavir.